



Domain Therapeutics reaches two milestones in multi-target research collaboration with Boehringer Ingelheim

Less than one year after signing agreement, the GPCR expert has reached key discovery milestones in two independent projects

Strasbourg, France, September 30, 2019 – Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting transmembrane receptors in neurology, oncology and rare diseases, today announces the achievement of two discovery milestones in its multi-target collaboration with Boehringer Ingelheim.

These milestones illustrate the ability of Domain Therapeutics to address orphan GPCRs using its proprietary platforms, DTect-All™ and bioSens-All™. Financial details were not disclosed.

“Collaborating with a partner such as Boehringer Ingelheim is a great opportunity and another excellent endorsement of our expertise with challenging GPCRs,” said Pascal Neuville, CEO of Domain Therapeutics. “We are very proud to have achieved, on time, the two first milestones of this collaboration and we look forward to building on this success.”

The two companies pursue the collaboration on the ongoing projects with the final objective to nominate preclinical candidates for the treatment of neuropsychiatric diseases.

About G Protein-Coupled Receptors

GPCRs belong to the family of membrane receptors and constitute one of the main classes of therapeutic targets for many indications. The binding of a hormone or a specific ligand to a receptor’s binding site activates one or several pathways for intracellular signaling. This enables the cell to provide an adapted response to the change in its environment. The many drugs that target GPCRs represent about 40% of all treatments on the market, but only address 15% of GPCRs. Thus, GPCRs remain largely underexploited to date.

Such receptors are widely expressed in the central nervous system where they play critical roles in regulating brain functions. A significant number of GPCRs are orphan receptors with no known ligand, making the corresponding drug discovery effort particularly challenging. Such complex targets are not addressable with conventional drug discovery approaches and require dedicated technologies.

About Domain Therapeutics

Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and early development of new drug candidates targeting transmembrane receptors, in particular G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. Domain identifies and develops candidates (allosteric modulators and biased ligands) through its innovative approach and technologies. Domain has three revenue generating pillars to its innovative business model: 1) collaboration with pharma companies for the discovery of new molecules, 2) out-licensing of its bioSens-All™ technology and 3) creation of asset centric vehicles for the development of its internal pipeline of preclinical candidates for central nervous system disorders and cancer. These asset-centric companies attract investment for focused development and exit is through a trade sale at an appropriate inflection point.

www.domaintherapeutics.com

Media and analysts contacts

Andrew Lloyd & Associates

Jo Reeder jo@ala.com / Juliette Schmitt Dos Santos juliette@ala.com

Tel: +44 1273 675 10 / @ALA_Group